A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host Disease
Phase of Trial: Phase I/II
Latest Information Update: 18 Mar 2019
At a glance
- Drugs Itolizumab (Primary) ; Corticosteroids
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms EQUATE
- Sponsors Equillium
- 11 Mar 2019 Status changed from not yet recruiting to recruiting.
- 26 Feb 2019 According to an Equillium media release, the company expects to initiate this trial by the end of the first quarter of 2019.
- 02 Dec 2018 New trial record